Darovasertib

DB16059InvestigationalSmall molecule

IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).

Mechanism: Pharmacologically active on Protein kinase C and Serine/threonine-protein kinase N1
Curator reviewed
Formula / weight: C₂₂H₂₃F₃N₈O · 472.476 g/mol (avg)
Code names: IDE-196 · LXS-196

Resolves to

Compound

UNIIE0YF0M8O09CAS1874276-76-2ChEMBLCHEMBL3982723

Structure

InChIKeyXXJXHXJWQSCNPX-UHFFFAOYSA-NSMILESCC1(N)CCN(CC1)C1=CC=CN=C1NC(=O)C1=C(N)N=CC(=N1)C1=C(C=CC=N1)C(F)(F)F

Targets

Q16512PKN1

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Darovasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account